that the respondent
No.3 i.e. the National Pharmaceutical Pricing Authority (NPPA) is
wrongly interpreting DPCO 2013 to insist on price ceiling for
formulations ... also
challenged communication dated 20.06.2014 issued by respondent
No.3-NPPA to the Department of Pharmaceutical, which purports
to interpret DPCO 2013, contrary
that the respondent
No.3 i.e. the National Pharmaceutical Pricing Authority (NPPA) is
wrongly interpreting DPCO 2013 to insist on price ceiling for
formulations ... also
challenged communication dated 20.06.2014 issued by respondent
No.3-NPPA to the Department of Pharmaceutical, which purports
to interpret DPCO 2013, contrary
that the respondent
No.3 i.e. the National Pharmaceutical Pricing Authority (NPPA) is
wrongly interpreting DPCO 2013 to insist on price ceiling for
formulations ... also
challenged communication dated 20.06.2014 issued by respondent
No.3-NPPA to the Department of Pharmaceutical, which purports
to interpret DPCO 2013, contrary
issued by the National
Pharmaceutical Pricing Authority (hereinafter referred to as,
"NPPA"), New Delhi, it being illegal and ex facie ultra vires ... impugned communication dated 6th/10th April,
2018 issued by NPPA addressed to the Petitioner and also to
the order dated 07/03/2018 and further
authority under its control i.e.
National Pharmaceutical Pricing Authority (NPPA). On this basis, it was
claimed that petitioner No.1 was liable to deposit ... interest upto 10.03.2015.
24. Thereafter, on 15.02.2016, the respondent No.1, through NPPA,
issued demand notice to the petitioner No.1, claiming that
Knee Implants (whose prices were fixed
by National Pharmaceutical Pricing Authority ('NPPA') in 2017 and
2018) and Hip Implants as well ... ensure their
affordability. The implementation of DPCO 2013 is overseen by the NPPA. Prices of
such drugs are merely monitored by the NPPA
Knee Implants (whose prices were fixed
by National Pharmaceutical Pricing Authority ('NPPA') in 2017 and
2018) and Hip Implants as well ... ensure their
affordability. The implementation of DPCO 2013 is overseen by the NPPA. Prices of
such drugs are merely monitored by the NPPA
Knee Implants (whose prices were fixed
by National Pharmaceutical Pricing Authority ('NPPA') in 2017 and
2018) and Hip Implants as well ... ensure their
affordability. The implementation of DPCO 2013 is overseen by the NPPA. Prices of
such drugs are merely monitored by the NPPA
Knee Implants (whose prices were fixed
by National Pharmaceutical Pricing Authority ('NPPA') in 2017 and
2018) and Hip Implants as well ... ensure their
affordability. The implementation of DPCO 2013 is overseen by the NPPA. Prices of
such drugs are merely monitored by the NPPA
Knee Implants (whose prices were fixed
by National Pharmaceutical Pricing Authority ('NPPA') in 2017 and
2018) and Hip Implants as well ... ensure their
affordability. The implementation of DPCO 2013 is overseen by the NPPA. Prices of
such drugs are merely monitored by the NPPA
